Summary
This project aims to study the role of soluble Izumo1 in activating regulatory pathways to attenuate inflammation and induce remission in Systemic Lupus Erythematosus (SLE) patients.
Izumo1 in remission in SLE
US · IL
NIH RePORTER
grant
open
#nih-5R21AI183113-02
What they want
The project will investigate soluble Izumo1 as a potential candidate involved in long-term remission in SLE. It will involve studying a large prospective cohort of SLE patients to gather clinical and functional evidence to support or refute the hypothesis that increased soluble Izumo1 levels act as a compensatory mechanism to activate regulatory pathways that reduce inflammation in SLE. The ultimate goal is to identify a novel biomarker and potential therapeutic target for inducing remission in SLE.
